Gas-phase stability of double-stranded oligodeoxynucleotides and their noncovalent complexes with DNA-binding drugs as revealed by collisional activation in an ion trap.
The intrinsic (gas-phase) stabilities of duplex, self-complementary oligonucleotides were measured in a relative way by subjecting the duplex precursor ions to increasing amounts of collision energy during the collisional-activated decomposition (CAD) events in an ion-trap mass spectrometer. The results are displayed as a dissociation profile, an s-shaped curve that shows the dependence of the relative abundance of the duplex on the applied collision energy. The total number of charges, the total number of base pairs, and the location of the high proton-affinity bases (i.e., G and C) are the main factors that affect the intrinsic stability of the duplex oligonucleotides. If the charge state is the same, the stability, as measured as a half-wave collision energy, E1/2, correlates well with the total number of H bonds for the duplex. The intrinsic stabilities of noncovalent complexes between duplex oligonucleotide and some DNA-binding drugs were also measured by using the newly developed method. Although duplexes are stabilized in the gas phase when they bind to drug molecules, correlations between gas-phase stabilities and the solution-binding affinities have not yet been obtained. Complexes in which the drug is bound in the minor groove must be joined tightly because they tend to dissociate in the gas phase by breaking covalent bonds of the oligonucleotide to give base loss and small sequence-ion formation. Complexes in which the drug is known to favor intercalation dissociate by breaking weak, noncovalent bonds to form single-stranded oligonucleotides although cleavage of covalent bonds of the oligonucleotide also occurs.
Wan
K X
KX
Department of Chemistry, Washington University, St. Louis, Missouri 63130, USA.
Gross
M L
ML
Shibue
T
T
D004247:DNA / Q000737:chemistry*; D005583:Fourier Analysis; D006860:Hydrogen Bonding; D013058:Mass Spectrometry; D009838:Oligodeoxyribonucleotides / Q000737:chemistry*; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000378:metabolism; D011166:Porphyrins / Q000737:chemistry
D009838:Oligodeoxyribonucleotides; D004364:Pharmaceutical Preparations; D011166:Porphyrins; D004247:DNA